B
GSK plc GSK
$46.66 -$0.45-0.95% NYSE
Recommendation
Prev Close
$47.10
Volume
3,130,685
Avg Vol (90D)
5,139,676
Market Cap
$93.27B
Dividend & Yield
$1.62(3.44%)
52-Week Range
$31.72 - $47.21
P/E (TTM)
26.84
EPS (TTM)
$1.75
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Merck: 4 No-Brainer Reasons to Buy This Dip
2/10/2025 - MarketBeat
GSK (GSK) Highlights Liver Disease Research Developments at AASLD 2025
11/7/2025 - GuruFocus
GSK presents data from liver pipeline at AASLD 2025
11/7/2025 - The Fly
Eli Lilly's weight-loss drug Mounjaro is India's top-selling drug in October - Reuters
11/7/2025 - Seeking Alpha - Healthcare
Alembic receives USFDA approval for its first drug device combination product
11/7/2025 - Business Standard - Markets & Investing
Eli Lilly's Weight-Loss Drug Mounjaro Becomes India's Top-Selling Medicine By Value: Report
11/7/2025 - Stocktwits News Feed
U.S. launches pilot payment model to bring MFN pricing to Medicaid
11/7/2025 - Seeking Alpha - Healthcare
J.P. Morgan Reaffirms Their Sell Rating on GlaxoSmithKline (GSK)
11/7/2025 - TipRanks Financial Blog
GSK Pharma shares fall 3% as revenue misses expectations; Q2 breakdown here
11/7/2025 - Business Standard - Markets & Investing
Stock Alert: Goodyear India, Crompton Greaves Consumer Electricals, GMM Pfaudler, GlaxoSmithKline Pharma
11/7/2025 - Business Standard - Markets & Investing
Pensions funds MUST back Britain: Business chiefs demand Reeves do more to boost investment
11/6/2025 - Money Mail Online
Novo, Eli Lilly oral obesity drugs included in new FDA priority voucher program
11/6/2025 - Seeking Alpha - Healthcare
FDA Recognizes GSK's Dostarlimab for Rectal Cancer in Latest Voucher Pilot
11/6/2025 - GuruFocus
FDA awards second batch of National Priority Vouchers
11/6/2025 - TipRanks Financial Blog
Market Update: CMG, GSK, QCOM
11/6/2025 - Yahoo! Finance: News
Moderna Q3 Earnings Beat, Stock Up on Revised '25 Spending Plans
11/6/2025 - Zacks Investment Research
Glaxosmithkline Pharmaceuticals consolidated net profit rises 1.98% in the September 2025 quarter
11/6/2025 - Business Standard - Markets & Investing
GSK (GLAXF, $23.46) price may drop as it broke higher Bollinger Band on Nov 05, 2025
11/6/2025 - Tickeron - Stocks
GSK's retreat on diversity targets felt by employees
11/6/2025 - FT.com - Pharmaceuticals
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
11/5/2025 - Zacks Investment Research
GSK PLC (GSK) Q3 2025 Earnings Call Highlights: Strong Sales Growth and Upgraded Guidance
11/5/2025 - GuruFocus
Q3 2025 GSK plc Earnings Call Transcript
11/4/2025 - GuruFocus
GSK (LON:GSK) Given New GBX 2,100 Price Target at Jefferies Financial Group
11/4/2025 - MarketBeat
I mingled with 10,000 doctors and scientists near CDC headquarters. It was like looking into a public-health crystal ball.
11/4/2025 - Insider
After a Reset Year, Is Moderna Stock Poised for a Comeback?
1/22/2025 - MarketBeat
Income Statement
Total Revenue (TTM)
$42.05B
EBITDA (TTM)
$15.47B
EBIT (TTM)
$11.20B
Net Income (TTM)
$7.22B
Balance Sheet
Total Assets (Q)
$82.45B
Total Debt (Q)
$23.86B
Total Liabilities (Q)
$61.28B
Book Value Per Share (Q)
$5.81
Cash Flow
Cash from Operations (TTM)
$10.22B
Cash from Investing (TTM)
-$5.77B
Cash from Financing (TTM)
-$4.94B
Net Change in Cash (TTM)
-$451.89M
Filings
Filing Date
Wednesday, October 29, 2025
Period Date
Tuesday, September 30, 2025
Next Filing
Week of Feb 23 and 27 (est)
Price History
Loading...
Beta
0.59
7-Day Total Return
1.57%
30-Day Total Return
17.06%
60-Day Total Return
20.21%
90-Day Total Return
22.46%
Year to Date Total Return
42.04%
1-Year Total Return
32.97%
2-Year Total Return
44.66%
3-Year Total Return
64.70%
5-Year Total Return
52.42%
52-week Low
Jan 14, 2025 - $31.72
52-week High
Nov 06, 2025 - $47.21
Valuation
Market Cap
$93.27B - Large Cap
Enterprise Value
$111.60B
Price/Sales (TTM)
4.59
Price/Book (Q)
8.11
Dividends and Shares
Shares Outstanding
4.10K
Dividend Per Share (Most Recent)
$0.42
Dividend Per Share (TTM)
$1.62
Corporate Info
Website
www.gsk.com
Phone Number
44 20 8047 5000
Address
79 New Oxford Street
London, WC1A 1DG
Country
United Kingdom
Year Founded
1715
Business Description
Sector
--
Industry
--
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United... more
NYSE 11/07/2025 1:45PM Eastern Quotes delayed